Evaxion A/S Appoints New CEO

Evaxion A/S, a clinical-stage TechBio company specializing in AI-Immunology™ powered vaccines, announced the appointment of Dr. Helen Tayton-Martin as its new Chief Executive Officer (CEO) effective November 24, 2025. Dr. Tayton-Martin brings over 30 years of experience in biotech, including leadership roles in cancer immunotherapy and strategic partnerships. She previously served as Chief Operating Officer and Chief Business & Strategy Officer at Adaptimmune, where she oversaw significant growth and collaborations. Dr. Tayton-Martin will step down from Evaxion's Board of Directors upon assuming the CEO role. Additionally, Jens Bitsch-Norhave, a seasoned life science executive, will join the Board as an adviser and observer, with the intention of seeking election at the 2026 Annual General Meeting. Birgitte Rønø, who served as interim CEO, will continue in her role as Chief Scientific Officer.